Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:6196430rdf:typepubmed:Citationlld:pubmed
pubmed-article:6196430lifeskim:mentionsumls-concept:C0015576lld:lifeskim
pubmed-article:6196430lifeskim:mentionsumls-concept:C0567416lld:lifeskim
pubmed-article:6196430lifeskim:mentionsumls-concept:C0024264lld:lifeskim
pubmed-article:6196430lifeskim:mentionsumls-concept:C0003320lld:lifeskim
pubmed-article:6196430lifeskim:mentionsumls-concept:C0034793lld:lifeskim
pubmed-article:6196430lifeskim:mentionsumls-concept:C0068655lld:lifeskim
pubmed-article:6196430lifeskim:mentionsumls-concept:C0079717lld:lifeskim
pubmed-article:6196430lifeskim:mentionsumls-concept:C1334146lld:lifeskim
pubmed-article:6196430lifeskim:mentionsumls-concept:C1366562lld:lifeskim
pubmed-article:6196430lifeskim:mentionsumls-concept:C1706439lld:lifeskim
pubmed-article:6196430lifeskim:mentionsumls-concept:C1412206lld:lifeskim
pubmed-article:6196430lifeskim:mentionsumls-concept:C0205214lld:lifeskim
pubmed-article:6196430lifeskim:mentionsumls-concept:C0006599lld:lifeskim
pubmed-article:6196430pubmed:issue6lld:pubmed
pubmed-article:6196430pubmed:dateCreated1984-1-26lld:pubmed
pubmed-article:6196430pubmed:abstractTextThe human lymphocyte function-associated antigen-1 (LFA-1), the complement receptor-associated OKM1 molecule, and a previously undescribed molecule termed p150,95, have been found to be structurally and antigenically related. Each antigen contains an alpha- and beta-subunit noncovalently associated in an alpha 1 beta 1-structure as shown by cross-linking experiments. LFA-1, OKM1, and p150,95 alpha-subunit designations and their molecular weights are alpha L = 177,000 Mr, alpha M = 165,000 Mr, and alpha X = 150,000 Mr, respectively. The beta-subunits are all = 95,000 Mr. Some MAb precipitated only LFA-1, others only OKM1, and another precipitates all three antigens. The specificity of these MAb for particular subunits was examined after subunit dissociation by high pH. MAb specific for LFA-1 or OKM1 bind to the alpha L- or alpha M-subunits, respectively, while the cross-reactive MAb binds to the beta-subunits. Coprecipitation experiments with intact alpha 1 beta 1-complexes showed anti-alpha and anti-beta MAb can precipitate the same molecules. In two-dimensional (2D) isoelectric focusing-SDS-PAGE, the alpha subunits of the three antigens are distinct, while the beta-subunits are identical. Biosynthesis experiments showed alpha L, alpha M, and alpha X are synthesized from distinct precursors, as is beta. The three antigens differ in expression on lymphocytes, granulocytes, and monocytes. During maturation of the monoblast-like U937 line, alpha M and alpha X are upregulated and alpha L is downregulated. Some MAb to the alpha subunit of OKM1 inhibited the complement receptor type three. LFA-1, OKM1, and p150,95 constitute a novel family of functionally important human leukocyte antigens that share a common beta-subunit.lld:pubmed
pubmed-article:6196430pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6196430pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6196430pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6196430pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6196430pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6196430pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6196430pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6196430pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6196430pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6196430pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6196430pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6196430pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6196430pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6196430pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6196430pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6196430pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6196430pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6196430pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6196430pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6196430pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6196430pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6196430pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6196430pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6196430pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6196430pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6196430pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6196430pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6196430pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6196430pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6196430pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6196430pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6196430pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6196430pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6196430pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6196430pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6196430pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6196430pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6196430pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6196430pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6196430pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6196430pubmed:languageenglld:pubmed
pubmed-article:6196430pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6196430pubmed:citationSubsetIMlld:pubmed
pubmed-article:6196430pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6196430pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6196430pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6196430pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6196430pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6196430pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6196430pubmed:statusMEDLINElld:pubmed
pubmed-article:6196430pubmed:monthDeclld:pubmed
pubmed-article:6196430pubmed:issn0022-1007lld:pubmed
pubmed-article:6196430pubmed:authorpubmed-author:SimonPPlld:pubmed
pubmed-article:6196430pubmed:authorpubmed-author:RobbinsEElld:pubmed
pubmed-article:6196430pubmed:authorpubmed-author:SpringerT ATAlld:pubmed
pubmed-article:6196430pubmed:authorpubmed-author:Sanchez-Madri...lld:pubmed
pubmed-article:6196430pubmed:authorpubmed-author:NagyJ AJAlld:pubmed
pubmed-article:6196430pubmed:issnTypePrintlld:pubmed
pubmed-article:6196430pubmed:day1lld:pubmed
pubmed-article:6196430pubmed:volume158lld:pubmed
pubmed-article:6196430pubmed:ownerNLMlld:pubmed
pubmed-article:6196430pubmed:authorsCompleteYlld:pubmed
pubmed-article:6196430pubmed:pagination1785-1803lld:pubmed
pubmed-article:6196430pubmed:dateRevised2009-11-18lld:pubmed
pubmed-article:6196430pubmed:meshHeadingpubmed-meshheading:6196430-...lld:pubmed
pubmed-article:6196430pubmed:meshHeadingpubmed-meshheading:6196430-...lld:pubmed
pubmed-article:6196430pubmed:meshHeadingpubmed-meshheading:6196430-...lld:pubmed
pubmed-article:6196430pubmed:meshHeadingpubmed-meshheading:6196430-...lld:pubmed
pubmed-article:6196430pubmed:meshHeadingpubmed-meshheading:6196430-...lld:pubmed
pubmed-article:6196430pubmed:meshHeadingpubmed-meshheading:6196430-...lld:pubmed
pubmed-article:6196430pubmed:meshHeadingpubmed-meshheading:6196430-...lld:pubmed
pubmed-article:6196430pubmed:meshHeadingpubmed-meshheading:6196430-...lld:pubmed
pubmed-article:6196430pubmed:meshHeadingpubmed-meshheading:6196430-...lld:pubmed
pubmed-article:6196430pubmed:meshHeadingpubmed-meshheading:6196430-...lld:pubmed
pubmed-article:6196430pubmed:meshHeadingpubmed-meshheading:6196430-...lld:pubmed
pubmed-article:6196430pubmed:meshHeadingpubmed-meshheading:6196430-...lld:pubmed
pubmed-article:6196430pubmed:meshHeadingpubmed-meshheading:6196430-...lld:pubmed
pubmed-article:6196430pubmed:meshHeadingpubmed-meshheading:6196430-...lld:pubmed
pubmed-article:6196430pubmed:meshHeadingpubmed-meshheading:6196430-...lld:pubmed
pubmed-article:6196430pubmed:year1983lld:pubmed
pubmed-article:6196430pubmed:articleTitleA human leukocyte differentiation antigen family with distinct alpha-subunits and a common beta-subunit: the lymphocyte function-associated antigen (LFA-1), the C3bi complement receptor (OKM1/Mac-1), and the p150,95 molecule.lld:pubmed
pubmed-article:6196430pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:6196430pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
More...